Compugen (NASDAQ:CGEN) Downgraded by StockNews.com

StockNews.com cut shares of Compugen (NASDAQ:CGEN) from a buy rating to a hold rating in a research report report published on Tuesday morning.

Separately, Truist Financial decreased their target price on Compugen from $5.00 to $4.00 and set a buy rating on the stock in a research note on Tuesday, May 21st.

Compugen Stock Up 1.0 %

Shares of NASDAQ CGEN opened at $2.07 on Tuesday. The firm has a market capitalization of $179.30 million, a P/E ratio of -10.42 and a beta of 2.71. The stock’s 50-day simple moving average is $2.11 and its two-hundred day simple moving average is $2.04. Compugen has a twelve month low of $0.53 and a twelve month high of $3.03.

Compugen (NASDAQ:CGEN) last announced its earnings results on Monday, May 20th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. The business had revenue of $2.56 million during the quarter, compared to the consensus estimate of $2.79 million. As a group, research analysts anticipate that Compugen will post 0.05 EPS for the current fiscal year.

Hedge Funds Weigh In On Compugen

Several institutional investors have recently modified their holdings of CGEN. Heron Bay Capital Management bought a new position in shares of Compugen during the 1st quarter valued at about $32,000. Tocqueville Asset Management L.P. bought a new position in shares of Compugen during the 3rd quarter valued at about $71,000. Finally, Silverarc Capital Management LLC increased its position in shares of Compugen by 6.1% during the 3rd quarter. Silverarc Capital Management LLC now owns 350,188 shares of the biotechnology company’s stock valued at $326,000 after purchasing an additional 20,000 shares during the last quarter. 12.22% of the stock is currently owned by institutional investors.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.